NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis

Not Yet RecruitingPhase 4

Sponsor: Tanta University

Conditions: Rheumatoid Arthritis

Interventions: Baricitinib

Countries: Egypt

This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adults aged ≥ 18 years.
* Diagnosis of rheumatoid arthritis according to the ACR/EULAR 2010 criteria.
* Patients with active rheumatoid arthritis despite conventional treatment.
* Ability to provide written informed consent.

Exclusion Criteria:

* Presence of other autoimmune diseases.
* Diabetes mellitus.
* Dyslipidemia or use of lipid-lowering therapy within the last 6 months.
* Chronic kidney disease.
* Chronic liver disease.
* Chronic respiratory disease.
* History of malignancy.
* Pregnancy or breastfeeding.
* Alcohol or drug abuse.
* Acute or chronic infection.
* Current prednisone dose \> 7.5 mg/day.
* History of arterial or venous thrombosis.
* Use of anticoagulant or antithrombotic drugs within the last 3 months.

Locations (1)

Tanta, Egypt